

FOR GENERAL RELEASE TO THE PUBLIC
March 3, 2022

Announcement Regarding the Result of the Investigation by the Competition Board

In our special case announcement made on November 11, 2020 mentioned that the Competition Board, after conducting the preliminary inquiry on some companies including our MLP Sağlık Hizmetleri A.Ş. (“Company”) and its subsidiary Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. (“Samsun Medikal”), had decided to initiate an investigation as per its decision dated October 15, 2020 and numbered 20-46/624-M, in order to determine whether there is a violation of The Act on the Protection of Competition No.4054 pursuant to Article 4 of the Law No.4054 and within this context had invited us to put forward our defence.

The relevant investigation was concluded and according to the decision, a total of TL 58.0 million administrative fine was imposed on 18 private health institutions and an enterprise union.

Based on this decision, a total administrative fine of TL 10.8 million to Samsun Medikal, an affiliate 80% of which owned by our Company, and of TL 18.7 million to our Company was imposed.

The Competition Board fine will be paid within 30 days by taking advantage of a 25% early payment discount by preserving the right of all kinds of objections and lawsuits.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.